NeoGenomics Inc (NEO)
14.16
+0.74
(+5.51%)
USD |
NASDAQ |
Apr 23, 16:00
14.25
+0.09
(+0.64%)
Pre-Market: 08:42
NeoGenomics Cash from Financing (TTM): 4.554M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 4.554M |
September 30, 2023 | 5.086M |
June 30, 2023 | 6.204M |
March 31, 2023 | 7.151M |
December 31, 2022 | 11.83M |
September 30, 2022 | 12.49M |
June 30, 2022 | 2.808M |
March 31, 2022 | 206.41M |
December 31, 2021 | 725.28M |
September 30, 2021 | 731.09M |
June 30, 2021 | 741.92M |
March 31, 2021 | 759.92M |
December 31, 2020 | 235.60M |
September 30, 2020 | 224.17M |
June 30, 2020 | 220.20M |
March 31, 2020 | 159.60M |
December 31, 2019 | 159.47M |
September 30, 2019 | 167.17M |
June 30, 2019 | 269.82M |
March 31, 2019 | 99.69M |
December 31, 2018 | 91.96M |
September 30, 2018 | 85.74M |
June 30, 2018 | -20.90M |
March 31, 2018 | -14.55M |
December 31, 2017 | -4.095M |
Date | Value |
---|---|
September 30, 2017 | -17.42M |
June 30, 2017 | -14.14M |
March 31, 2017 | -12.44M |
December 31, 2016 | -25.87M |
September 30, 2016 | 49.93M |
June 30, 2016 | 49.64M |
March 31, 2016 | 49.08M |
December 31, 2015 | 58.49M |
September 30, 2015 | -2.922M |
June 30, 2015 | 30.70M |
March 31, 2015 | 27.79M |
December 31, 2014 | 29.01M |
September 30, 2014 | 30.55M |
June 30, 2014 | -3.236M |
March 31, 2014 | -1.17M |
December 31, 2013 | 2.75M |
September 30, 2013 | 1.996M |
June 30, 2013 | 4.255M |
March 31, 2013 | 5.206M |
December 31, 2012 | 3.384M |
September 30, 2012 | 2.502M |
June 30, 2012 | 1.617M |
March 31, 2012 | 1.815M |
December 31, 2011 | 2.359M |
September 30, 2011 | 2.344M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.808M
Minimum
Jun 2022
759.92M
Maximum
Mar 2021
244.78M
Average
167.17M
Median
Sep 2019
Cash from Financing (TTM) Benchmarks
Teladoc Health Inc | 10.85M |
Abbott Laboratories | -7.091B |
Halozyme Therapeutics Inc | -407.99M |
Verastem Inc | 134.19M |
Ocugen Inc | 20.88M |